International – Sanofi and Translate Bio launch phase 1/2 trial of mRNA-based COVID-19 vaccine

Sanofi and Translate Bio have announced the launch of a phase 1/2 trial evaluating their mRNA-based COVID-19 vaccine candidate MRT5500.

The randomised, placebo-controlled trial will evaluate the safety, tolerability and immunogenicity of MRT5500 and is expected to enrol 415 healthy adults aged 18 years and older.

Participants taking part in the phase 1/2 trial will receive one dose of MRT5500 or two doses administered 21 days apart. Sanofi and Translate will investigate three different dose levels of the vaccine candidate – 15µg, 45µg or 135µg.

The companies added that preclinical studies are also ongoing and are set to continue over the coming months…